Identification of fluocinolone acetonide to prevent paclitaxel-induced peripheral neuropathy

Aysel Cetinkaya-Fisgin, Min Geol Joo, Xiang Ping, Nitish V. Thakor, Cengizhan Ozturk, Ahmet Hoke, In Hong Yang

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Paclitaxel (PTX) is among the most commonly used cancer drugs that cause chemotherapy-induced peripheral neuropathy (CIPN), a debilitating and serious dose-limiting side effect. Currently, no drugs exist to prevent CIPN, and symptomatic therapy is often ineffective. In order to identify therapeutic candidates to prevent axonal degeneration induced by PTX, we carried out a phenotypic drug screening using primary rodent dorsal root ganglion sensory neurons. We identified fluocinolone acetonide as a neuroprotective compound and verified it through secondary screens. Furthermore, we showed its efficacy in a mouse model of PTX-induced peripheral neuropathy and confirmed with four different cancer cell lines that fluocinolone acetonide does not interfere with PTX's antitumor activity. Our study identifies fluocinolone acetonide as a potential therapy to prevent CIPN caused by PTX.

Original languageEnglish (US)
Pages (from-to)128-133
Number of pages6
JournalJournal of the Peripheral Nervous System
Issue number3
StatePublished - 2016


  • chemotherapy-induced peripheral neuropathy
  • fluocinolone acetonide
  • paclitaxel
  • phenotypic drug screening

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology


Dive into the research topics of 'Identification of fluocinolone acetonide to prevent paclitaxel-induced peripheral neuropathy'. Together they form a unique fingerprint.

Cite this